Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

Rhea-AI Summary

Revance Therapeutics, Inc. (RVNC) will release its third quarter 2023 financial results on November 8, 2023, after the market closes. A conference call and live webcast will be held on the same day at 4:30 p.m. ET to discuss the results and provide a corporate update. Interested individuals can dial (833) 470-1428 to listen to the conference call or access the webcast link on the company's website. A webcast replay will be available until February 8, 2024.

Conference Call Scheduled for Wednesday, November 8, 2023 at 4:30 p.m. ET

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (RVNC) today announced that the company will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S. and Canadian callers, and reference conference ID 509643 or from the webcast link in the investor relations section of the company's website at: www.revance.com.

A webcast replay will be available beginning November 8, 2023, at 4.30 p.m. PT / 7.30 p.m. ET to February 8, 2024 at 4.30 p.m. PT / 7.30 p.m. ET. To access the replay, please register via the webcast link on the events page. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China.

Revance is headquartered in Nashville, Tenn., with additional office locations in Newark and Irvine, Calif. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, www.hcp.DAXXIFYTherapy.com, or connect with us on LinkedIn.

“Revance” and the Revance logo, and DAXXIFY® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered trademark of Allergan, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231101838360/en/

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 510-279-6886

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com



Media

Revance Therapeutics, Inc.:

Sara J. Fahy, 949-887-4476

sfahy@revance.com

Source: Revance Therapeutics, Inc.

FAQ

When will Revance Therapeutics release its third quarter 2023 financial results?

Revance Therapeutics will release its third quarter 2023 financial results on November 8, 2023, after the market closes.

What time is the conference call and live webcast scheduled?

The conference call and live webcast are scheduled for 4:30 p.m. ET on November 8, 2023.

How can I listen to the conference call?

To listen to the conference call, you can dial (833) 470-1428 if you are in the U.S. or Canada. The conference ID is 509643. Alternatively, you can access the webcast link on the investor relations section of Revance Therapeutics' website.

How long will the webcast replay be available?

The webcast replay will be available from November 8, 2023, at 4:30 p.m. PT / 7:30 p.m. ET until February 8, 2024, at 4:30 p.m. PT / 7:30 p.m. ET.